PURPLE BIOTECH LTD. of REHOVOT, L3, a company, filed a Form D exempt-offering notice with the SEC on 2024-07-15. The offering totals $4.5M, of which $4.5M was reported sold. Industry: Biotechnology.
Showing 25 of 30 people.
| Name | Role | Location |
|---|---|---|
| Ido Agmon | Director | Rehovot, L3 |
| Robert Gagnon | Director | Rehovot, L3 |
| Ori Hershkovitz | Director | Rehovot, L3 |
| Isaac Israel | Director | TEL AVIV, L3 |
| Yael Margolin | Director | Rehovot, L3 |
| Suzana Nahum-Zilberberg | Director | Rehovot, L3 |
| Simcha Rock | Director | Rehovot, L3 |
| Eric Rowinsky | Director | Rehovot, L3 |
| Gil Efron | Executive Officer | Rehovot, L3 |
| Lior Fhima | Executive Officer | Rehovot, L3 |
| Ido Morpurgo | Executive Officer | Rehovot, L3 |
| Hadas Reuveni | Executive Officer | Rehovot, L3 |
| Michael Schickler | Executive Officer | Rehovot, L3 |
| Avraham Ben-Tzvi | Executive Officer | Berkeley Heights, NJ |
| Simcha Rock | Executive Officer | Rehovot, L3 |
| Isaac Israel | Executive Officer | TEL AVIV, L3 |
| Fabien Sebille | Executive Officer | Rehovot, L3 |
| Ran Tzror | Director | Tel Aviv, L3 |
| Steven Steinberg | Director | Tel Aviv, L3 |
| Revital Stern-Raff | Director | Tel Aviv, L3 |
| Bertrand Liang | Executive Officer | Tel Aviv, L3 |
| Gil Ben-Menachem | Director | Tel Aviv, L3 |
| Gil Ben-Menachem | Executive Officer | Tel Aviv, L3 |
| John Paul Waymack | Director | Tel Aviv, L3 |
| John Paul Waymack | Executive Officer | Tel Aviv, L3 |
| Filed | Form | Offering | Sold |
|---|---|---|---|
| 2023-10-31 | D | $5.4M | $5.4M |
| 2020-07-14 | D | — | — |
| 2020-05-15 | D | $10.0M | $10.0M |
| 2020-05-04 | D | $6.5M | $6.5M |
| 2020-01-21 | D | — | — |
| 2019-01-24 | D | $6.0M | $6.0M |
| 2018-06-07 | D | $8.2M | $8.2M |
| 2018-03-26 | D | — | — |
| 2017-11-01 | D | — | — |
| 2017-08-08 | D | $2.0M | $2.0M |
| 2016-05-02 | D | — | — |
| 2016-02-04 | D | — | — |